Drug Profile
Research programme: multiple myeloma therapeutics - Xencor
Alternative Names: XmAb 5592Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Xencor
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 22 Apr 2009 Preclinical trials in Multiple myeloma in USA (Parenteral)